Kidney patients needed to test how drug moves in body
NCT ID NCT07426380
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study looks at how the drug eloralintide enters the bloodstream and leaves the body in people with severe kidney disease or kidney failure, compared to healthy volunteers. About 28 participants will receive a single shot under the skin. The study lasts about 14 weeks and does not aim to treat any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Floridian Clinical Research, LLC
ACTIVE_NOT_RECRUITINGMiami Lakes, Florida, 33016-1518, United States
-
Omega Research Orlando LLC
RECRUITINGOrlando, Florida, 32808, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Can a new drug work safely in patients with kidney failure?
- Can a simple foot pump ease leg swelling in hospital patients?
- Can a damaged kidney change how antibiotics work?
- Could your blood type predict kidney treatment success?
- Can community hospitals in zambia master severe disease care?